Personalis (NASDAQ:PSNL) Stock Price Expected to Rise, HC Wainwright Analyst Says

Personalis (NASDAQ:PSNL) had its price target hoisted by analysts at HC Wainwright from $8.00 to $9.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 125.00% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC restated a “buy” rating and set a $7.00 price objective on shares of Personalis in a report on Thursday, April 10th. Lake Street Capital raised their target price on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, Craig Hallum started coverage on shares of Personalis in a report on Monday, March 17th. They issued a “buy” rating and a $8.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $8.00.

Personalis Stock Performance

Shares of NASDAQ:PSNL opened at $4.00 on Wednesday. The firm has a market cap of $353.23 million, a PE ratio of -2.38 and a beta of 1.83. The business has a fifty day moving average of $3.61 and a 200-day moving average of $4.45. Personalis has a twelve month low of $1.14 and a twelve month high of $7.20.

Personalis (NASDAQ:PSNL) last issued its earnings results on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The firm had revenue of $20.61 million for the quarter, compared to analysts’ expectations of $17.41 million. On average, analysts anticipate that Personalis will post -1.4 EPS for the current fiscal year.

Institutional Trading of Personalis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Personalis during the 4th quarter valued at about $28,000. JPMorgan Chase & Co. grew its holdings in shares of Personalis by 2,827.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock worth $34,000 after purchasing an additional 5,654 shares during the last quarter. Olympiad Research LP purchased a new stake in shares of Personalis during the fourth quarter worth about $59,000. Alpine Global Management LLC bought a new position in shares of Personalis during the fourth quarter valued at approximately $60,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Personalis by 18.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,704 shares of the company’s stock worth $62,000 after buying an additional 2,724 shares during the period. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.